MX2022004178A - Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. - Google Patents
Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.Info
- Publication number
- MX2022004178A MX2022004178A MX2022004178A MX2022004178A MX2022004178A MX 2022004178 A MX2022004178 A MX 2022004178A MX 2022004178 A MX2022004178 A MX 2022004178A MX 2022004178 A MX2022004178 A MX 2022004178A MX 2022004178 A MX2022004178 A MX 2022004178A
- Authority
- MX
- Mexico
- Prior art keywords
- heterobycyclic
- blockers
- potassium channel
- aryl compounds
- shaker type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911648P | 2019-10-07 | 2019-10-07 | |
| PCT/US2020/054393 WO2021071832A1 (en) | 2019-10-07 | 2020-10-06 | Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004178A true MX2022004178A (es) | 2022-06-16 |
Family
ID=75438321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004178A MX2022004178A (es) | 2019-10-07 | 2020-10-06 | Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230049231A1 (https=) |
| EP (1) | EP4041405A4 (https=) |
| JP (1) | JP7780440B2 (https=) |
| KR (1) | KR20220079878A (https=) |
| AU (1) | AU2020362118A1 (https=) |
| BR (1) | BR112022006292A2 (https=) |
| CA (1) | CA3157020A1 (https=) |
| IL (1) | IL291866A (https=) |
| MX (1) | MX2022004178A (https=) |
| WO (1) | WO2021071832A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023003841A (es) | 2020-10-06 | 2023-06-23 | De Shaw Res Llc | Compuestos lactámicos como bloqueadores del canal agitador de potasio kv1.3. |
| TW202521512A (zh) | 2023-07-31 | 2025-06-01 | 美商美國禮來大藥廠 | Kv1.3鉀shaker通道阻斷劑之固體形式及其使用方法 |
| WO2025161144A1 (zh) * | 2024-01-29 | 2025-08-07 | 上海深势唯思科技有限责任公司 | 芳基杂环类Kv1.3抑制剂及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6348486B1 (en) * | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
| JP4377231B2 (ja) * | 2001-11-05 | 2009-12-02 | 大日本住友製薬株式会社 | 新規なカルバペネム化合物 |
| US6939968B2 (en) * | 2002-12-23 | 2005-09-06 | Bristol-Myers Squibb Company | Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives |
| WO2005030729A1 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinoline potassium channel inhibitors |
| US7538110B2 (en) * | 2005-10-27 | 2009-05-26 | Adolor Corporation | Opioid antagonists |
| TWI370130B (en) * | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| WO2011073273A1 (en) * | 2009-12-16 | 2011-06-23 | Evotec Ag | Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators |
-
2020
- 2020-10-06 KR KR1020227013487A patent/KR20220079878A/ko not_active Withdrawn
- 2020-10-06 IL IL291866A patent/IL291866A/en unknown
- 2020-10-06 AU AU2020362118A patent/AU2020362118A1/en not_active Abandoned
- 2020-10-06 EP EP20873621.5A patent/EP4041405A4/en active Pending
- 2020-10-06 JP JP2022546592A patent/JP7780440B2/ja active Active
- 2020-10-06 MX MX2022004178A patent/MX2022004178A/es unknown
- 2020-10-06 BR BR112022006292A patent/BR112022006292A2/pt not_active IP Right Cessation
- 2020-10-06 CA CA3157020A patent/CA3157020A1/en active Pending
- 2020-10-06 WO PCT/US2020/054393 patent/WO2021071832A1/en not_active Ceased
- 2020-10-06 US US17/766,834 patent/US20230049231A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220079878A (ko) | 2022-06-14 |
| JP2022551199A (ja) | 2022-12-07 |
| EP4041405A4 (en) | 2023-10-18 |
| US20230049231A1 (en) | 2023-02-16 |
| WO2021071832A1 (en) | 2021-04-15 |
| AU2020362118A1 (en) | 2022-04-21 |
| JP7780440B2 (ja) | 2025-12-04 |
| IL291866A (en) | 2022-06-01 |
| CA3157020A1 (en) | 2021-04-15 |
| BR112022006292A2 (pt) | 2022-06-28 |
| CN114828963A (zh) | 2022-07-29 |
| EP4041405A1 (en) | 2022-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004127A (es) | Compuestos heterociclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| CO2022004305A2 (es) | Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3 | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| MX390625B (es) | Inhibidores selectivos de jak1. | |
| MX2019004578A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| MX2022004144A (es) | Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. | |
| MX2022004168A (es) | Compuestos aromaticos de arilmetileno a manera de bloqueadores del canal de potasio kv1.3. | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| JOP20230307A1 (ar) | مركبات سبيرو إندولينون باعتبارها حاصرات القنوات الهزازة للبوتاسيوم Kv1.3 | |
| MX2022004178A (es) | Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. | |
| BR112023005387A2 (pt) | Compostos lactam como bloqueadores de canais agitadores de potássio kv1.3 | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MX382290B (es) | Derivados biciclo hetorocíclicos sustituidos, útiles como inhibidores del canal de potasio medular externo renal (romk). | |
| MX2022004145A (es) | Compuestos heterociclicos de arilmetileno como bloqueadores del canal de potasio tipo shaker kv1.3. | |
| JOP20240119A1 (ar) | مشتقات نافثيريدينون لمعالجة مرض أو اضطراب | |
| PH12022551012A1 (en) | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease | |
| JOP20230233A1 (ar) | مركبات الأريل الحلقية غير المتجانسة باعتبارها حاصرات القنوات الهزازة للبوتاسيوم Kv1.3 | |
| MX2024004273A (es) | Derivado triciclico de pirimidina y aplicacion farmaceutica del mismo. | |
| EA202190150A1 (ru) | Аминопиримидонильные производные, способ их получения и фармацевтические композиции, содержащие их |